David Wang
Directeur/Bestuurslid bij BIOVAXYS TECHNOLOGY CORP.
Vermogen: 92 540 $ op 30-04-2024
Profiel
David Wang is currently the Chief Executive Officer at Encounter Technology Ltd., Director at BioVaxys Technology Corp., and Director at BioVaxys LLC.
Previously, he worked as the Chief Executive Officer at Beijing Century Medical.
Mr. Wang holds an MBA from the University of International Business.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
BIOVAXYS TECHNOLOGY CORP
1.03% | 08-02-2023 | 1 492 575 ( 1.03% ) | 92 540 $ | 30-04-2024 |
Actieve functies van David Wang
| Bedrijven | Functie | Begin |
|---|---|---|
| BIOVAXYS TECHNOLOGY CORP. | Directeur/Bestuurslid | - |
BioVaxys LLC
 BioVaxys LLC BiotechnologyHealth Technology BioVaxys LLC is a clinical stage biotechnology company, which engages in the development of immunotherapeutic vaccines for antiviral and individualized cancer therapy. It focuses on multihaptenized autologous vaccine that will initially be developed and marketed for melanoma and ovarian cancer. The company was founded by James Passin, Kenneth Kovan and David Berd and is headquartered in New York, NY. | Directeur/Bestuurslid | - |
| Encounter Technology Ltd. | Algemeen Directeur | - |
Eerdere bekende functies van David Wang
| Bedrijven | Functie | Einde |
|---|---|---|
| Beijing Century Medical | Algemeen Directeur | - |
Opleiding van David Wang
| University of International Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BIOVAXYS TECHNOLOGY CORP. | Non-Energy Minerals |
| Bedrijven in privébezit | 3 |
|---|---|
BioVaxys LLC
BioVaxys LLC BiotechnologyHealth Technology BioVaxys LLC is a clinical stage biotechnology company, which engages in the development of immunotherapeutic vaccines for antiviral and individualized cancer therapy. It focuses on multihaptenized autologous vaccine that will initially be developed and marketed for melanoma and ovarian cancer. The company was founded by James Passin, Kenneth Kovan and David Berd and is headquartered in New York, NY. | Health Technology |
| Beijing Century Medical | |
| Encounter Technology Ltd. |
